Biotransplant(BTRN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN)

BTRN 35.57

-0.8%

Nov 3 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Arthur Radley who wrote (1360)	7/11/2002 5:16:58 PM
From: Arthur Radley	Read Replies (1) of 1475

MEDI got their FDA letter about Flumist and considering all, I guess it was a positive in that additional trials will not be required. However, with us already in July, it appears that they will not make the flu season this year. This is based on the fact that MEDI hasn't given out any details as to what additional info is needed. As the one analyst mentioned in a previous post, any negative for MEDI and Flumist could be a positive for BTRN in that this might nudge MEDI to putting 507 on the top tier of attention....so any comments on the MEDI news today as it relates to this issue? Also, when I spoke with the CEO last week, he mentioned that MEDI had submitted the paperwork for the new indication for RA and that the go ahead should occur in July. But then he made a interesting side comment. He said that it would be up to MEDI to release any information on the start of the new trial. Can anyone think of any reason that a company would not release this info. Wouldn't this be considered key information for shareholder knowledge on material events? Still keeping the faith, but might need to be rebaptisted soooon!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next